Glycosmedia Weekly Diabetes News - 05/06/2022

Duration of diabetes and the risk of major cardiovascular events in women and men: a prospective cohort study of UK Biobank participants

The increased risk of CVD associated with longer duration of diabetes is similar in women and men, and thus cannot explain the higher excess risk from diabetes in women in this study population (Diabetes Research and Clinical Practice)

Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes

The United States Food and Drug Administration (FDA) has approved two GLP-1RAs, liraglutide 1.8 mg/d and exenatide extended-release (ER), for T2D in youth aged 10 years or older.2 However, little is known about GLP-1RA prescribing patterns in youth. The objective of this retrospective chart review was to explore GLP-1RA prescribing practices for adolescents with T2D (Diabetes, Obesity and Metabolism)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

The dapagliflozin-induced plasma volume contraction may contribute to the initial SBP reduction, while a reduction in SNS activity may contribute to the persistent SBP reduction (Cardiovascular Diabetology)

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

These findings indicate that the CV outcomes for semaglutide were similar regardless of baseline metformin use, which may also apply to all GLP-1RAs (Cardiovascular Diabetology)

Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Cotadutide is safe and effective in reducing plasma glucose levels, HbA1c and body weight in individuals with type 2 diabetes (BMC Endocrine Disorders)